CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a new CAR-T therapy targeting a specific protein highly expressed in non-Hodgkin lymphomas, addressing the issue of treatment resistance due to CD19 loss. It involves evaluating this target in NHL patients and conducting preclinical assessments using advanced models.
Non-Hodgkin lymphomas (NHL) are a group of blood cancers characterized by the expansion of malignant B lymphocytes creating tumors throughout the body.
The standard of care for patients with aggressive NHL is a combination of chemotherapy and immunotherapy.
Even though it is well tolerated, ~40% of the patients respond poorly and eventually relapse.
Novel personalized treatment options are now available for such individuals and engage patients’ own T cells genetically manipulated to express a ch…
INSTITUT JOSEP CARRERAS - CERCA
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
ONECHAIN IMMUNOTHERAPEUTICS S.L.
Spain, BARCELONA
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
